Hemifacial spasm:: Over 10 years of treatment with botulinum toxin

被引:10
作者
Pérez-Saldaña, M. T.
Parkhutik, V.
Bosca-Blasco, M. E.
Claramonte, B.
Burguera-Hernández, J. A.
机构
[1] Hosp Gen Castellon, Serv Neurol, E-12004 Castellon de La Plana, Spain
[2] Hosp La Fe, Serv Neurol, Valencia, Spain
关键词
blepharospasm; botulinum toxin; dystonia; facial myokymias; facial palsy; hemifacial spasm;
D O I
10.33588/rn.4510.2007464
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction. The short-term beneficial and adverse effects of treatment with botulinum toxin (BT) in hemifacial spasm (HS) are well documented, but this is not the case with its long-term derivatives. Aims. To describe the characteristics, the dose development, the side effects and the reason for giving up therapy in patients who have been on BT treatment for more than 10 years. We also sought to evaluate the effectiveness and safety of prolonged treatment in patients with HS. Patients and the methods. We reviewed the demographic and clinical characteristics of patients who had had HS for more than 10 years since follow-up began. We analysed the mean dose development of BT per visit and year, the number of sessions per year side effects and reasons for dropping out. We focused our attention on cases with more than 10 years continuous treatment. Results. The percentage of patients who had been on treatment for over ten years was 53.7%. The mean dose of BT per year rose progressively, and was significant (p < 0.05) during the first four years of treatment. There was no significant increase in the number of sessions. Altogether 46 side eftects were observed, ptosis being the most frequent. These occurred during the first years of the early stages of the technique. The most common cause of dropout was loss to follow-up in 22 patients, followed by death in I I cases. Conclusions. BT is a feasible, safe treatment option (with very few benign side effects) in the prolonged treatment of patients with HS.
引用
收藏
页码:582 / 586
页数:5
相关论文
共 29 条
[1]  
Au WL, 2004, ANN ACAD MED SINGAP, V33, P324
[2]  
BURGUERA JA, 2006, GUIA PATRONES COMUNE
[3]  
CHOON Y, 1993, J KOREAN MED SCI, V8, P334
[4]   A comparative study of primary and secondary hemifacial spasm [J].
Colosimo, C ;
Bologna, M ;
Lamberti, S ;
Avanzino, L ;
Marinelli, L ;
Fabbrini, G ;
Abbruzzese, G ;
Defazio, G ;
Berardelli, A .
ARCHIVES OF NEUROLOGY, 2006, 63 (03) :441-444
[5]  
COSTA J, 2007, BIBLIOTECA COCHRANE
[6]   Botulinum toxin A treatment for primary hemifacial spasm -: A 10-year multicenter study [J].
Defazio, G ;
Abbruzzese, G ;
Girlanda, P ;
Vacca, L ;
Currà, A ;
De Salvia, R ;
Marchese, R ;
Raineri, R ;
Roselli, F ;
Livrea, P ;
Berardelli, A .
ARCHIVES OF NEUROLOGY, 2002, 59 (03) :418-420
[7]   The structure and mode of action of different botulinum toxins [J].
Dolly, J. O. ;
Aoki, K. R. .
EUROPEAN JOURNAL OF NEUROLOGY, 2006, 13 :1-9
[8]   Botulinum toxin therapy of hemifacial spasm: comparing different therapeutic preparations [J].
Frei, K ;
Truong, DD ;
Dressler, D .
EUROPEAN JOURNAL OF NEUROLOGY, 2006, 13 :30-35
[9]   The long-term evolution of botulinum toxin dosage in the treatment of hemifacial spasms [J].
García-Torres, MA ;
Espiga, PJGR .
REVISTA DE NEUROLOGIA, 2004, 39 (06) :599-599
[10]  
GARCIARUIZ PJ, 2006, MOV DISORD S15, V21, pS329